WCN26-4964 Blood pressure-lowering effect of dapagliflozin correlates with salt intake, but dosen’t directly contribute to the renal protection in chronic kidney disease patients

Read full text Summarise with VIRAT
Authors: Mitsuhiro Nishimoto, Kyoko Awaji, Atsuhisa Sato
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

SGLT2 inhibitors improve renal outcomes in patients with CKD when used in combination with RAS inhibitors. SGLT2 inhibitors exert an antihypertensive effect through inhibition of sodium reabsorption without activation of the RAS, and this blood pressure (BP)-lowering effect is thought to contribute to their cardio-renal protective properties. Excessive salt intake attenuates the renoprotective effect of RAS inhibitors, while mineralocorticoid receptor (MR) antagonists suppress this attenuation (Nishimoto et al., Hypertension Research 2019).

Fields of Study & Subjects

Chronic Kidney Disease and Diabetes Blood Pressure and Hypertension Studies Diabetes Treatment and Management

Publication details

Journal / source
Kidney International Reports
Volume
11
Issue
4
Pages
104345–104345
Publication date
25 March 2026
Language
EN